# US 2021/0228733 A1 · Methods and compositions for theranostic nanoparticles

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0228733 A1
- Document ID: US20210228733A1
- Status: Published application
- Kind: A1
- Application number: 17/228,286
- Filed: 2021-04-12
- Published: 2021-07-29
- Earliest claimed: 2015-04-28
- Assignees: University of Central Florida Research Foundation, Inc.; Sanford Burnham Prebys Medical Discovery Institute at Lake Nona; Memorial Sloan Kettering Cancer Center
- Inventors: Annette Khaled; Jesus Manuel Perez Figueroa; Santimukul Santra; Charalambos Kaittanis; Oscar Santiesteban; Jan Grimm; Hampton Sessions
- Web page: https://patentgrep.com/patent/US20210228733A1

## CPC

- A61K 47/6869: {the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate}
- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 38/10: Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/6935: {the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol}
- A61K 51/1072: {the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate}
- A61K 51/1244: {microparticles or nanoparticles, e.g. polymeric nanoparticles}
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed are compositions and methods for identifying a solid tumor cell target. Compositions and methods for treating prostate cancer are also disclosed. Further, cancer therapeutic compositions comprising CT20p are disclosed. Nanoparticles that are conjugated with a targeting ligand that is a substrate for a solid tumor-specific cell protein are disclosed.

## Claims

### Claim 1

A method of identifying a solid tumor cell target, comprising, 1) contacting a cell with an effective amount of a composition comprising at least one nanoparticle conjugated with a targeting ligand that is a substrate for a solid tumor-specific cell protein, wherein the nanoparticle further comprises an imaging compound; 2) identifying one or more nanoparticles bound to the cells by using imaging devices; and optionally, 3) monitoring the solid tumor cell target by repeating 1) and 2).

### Claim 2 (depends on 1)

The method of claim 1, further comprising treating the solid tumor cell by killing or inhibiting its growth.

### Claim 3 (depends on 1, 2)

The method of claim 1 or 2, wherein the solid tumor cell is a prostate cancer cell.

### Claim 4 (depends on 3)

The method of claim 3, wherein the prostate cancer cell is castration resistant prostate cancer.

### Claim 5 (depends on 1, 2)

The method of claim 1 or 2, wherein the solid tumor cell is a breast cancer cell.

### Claim 6 (depends on 1, 2)

The method of claim 1 or 2, wherein the solid tumor cell is a colon cancer cell.

### Claim 7 (depends on 1, 2)

The method of claim 1 or 2, wherein the solid tumor cell is a pancreas cancer cell.

### Claim 8 (depends on 1, 2)

The method of claim 1 or 2, wherein the solid tumor cell is a lung cancer cell.

### Claim 9 (depends on 1, 2)

The method of claim 1 or 2, wherein the nanoparticle further comprises, in its hydrophobic interior, a therapeutic agent.

### Claim 10 (depends on 9)

The method of claim 9, wherein the therapeutic agent is CT20p or a mutant CT20 peptide.

### Claim 11 (depends on 9)

The method of claim 9, wherein the therapeutic agent is a mitotoxic peptide.

### Claim 12 (depends on 9)

The method of claim 9, wherein the therapeutic agent is an anti-metastatic agent.

### Claim 13 (depends on 9)

The method of claim 9, wherein the therapeutic agent is an antiandrogenic agent.

### Claim 14 (depends on 8)

The method of claim 8, wherein the therapeutic agent is an anti-neoplastic agent.

### Claim 15 (depends on 1, 2, 9)

The method of claim 1, 2 or 9, wherein the solid tumor-specific cell protein is prostate specific membrane antigen (PSMA).

### Claim 16 (depends on 1, 2, 9)

The method of claim 1, 2 or 9, wherein the nanoparticles are polymeric nanoparticles.

### Claim 17 (depends on 1, 2, 9)

The method of claim 1, 2 or 9, wherein the nanoparticles are hyperbranched polyester nanoparticles (HBPE-NPs).

### Claim 18 (depends on 1, 2, 9)

The method of claim 1, 2 or 9, wherein the targeting ligand is a folate compound.

### Claim 19 (depends on 1, 2, 9)

The method of claim 1, 2 or 9, wherein the targeting ligand is a glutamate compound.

### Claim 20 (depends on 1, 2, 9)

The method of claim 1, 2 or 9, wherein the targeting ligand is a polyglutamated folate compound.

### Claim 21 (depends on 1, 2, 9)

The method of claim 1 or 2 or 9, wherein the targeting ligand is glutamate azido urea.

### Claim 22 (depends on 1, 2, 9)

The method of claim 1, 2 or 9, wherein the targeting ligand is folate azido urea.

### Claim 23 (depends on 1, 2, 9)

The method of claim 1, 2 or 9, wherein the targeting ligand is glutamate azido urea.

### Claim 24 (depends on 1, 2, 9)

The method of claim 1, 2 or 9, wherein the targeting ligand is a bifunctional glutamate-folate hybridized compound.

### Claim 25 (depends on 1, 2, 9)

The method of claim 1, 2 or 9, wherein the nanoparticle comprises a chelating ligand such as desferrioxamine (DFO).

### Claim 26 (depends on 1, 2, 9)

The method of claim 1, 2 or 9, wherein the imaging compound is a PET detectable compound.

### Claim 27 (depends on 1, 2, 9)

The method of claim 1, 2 or 9, wherein the PET detectable compound is 89Zr.

### Claim 28 (depends on 1, 2, 9)

The method of claim 1, 2 or 9, wherein the PET detectable compound is CU or other PET detectable compounds.

### Claim 29 (depends on 1, 2, 9)

The method of claim 1, 2 or 9, wherein the composition comprises a polyglutamated folate-HBPE-DFO[CT20p]-nanoparticles.

### Claim 30 (depends on 1, 2, 9)

The method of claims 1, 2 or 9, wherein the nanoparticle further comprises PEG.

### Claim 31 (depends on 1, 2, 9)

The method of claims 1, 2 or 9, wherein the targeting ligand is at high density/valency.

### Claim 32 (depends on 1, 2, 9)

The method of claims 1, 2 or 9, wherein the targeting ligand is at low density/valency.

### Claim 33

A cancer therapeutic composition, comprising: at least one nanoparticle conjugated with a targeting ligand that is a substrate for a solid tumor-specific cell protein, wherein the nanoparticle further comprises an imaging compound and having a therapeutic agent encapsulated in the hydrophobic interior of the nanoparticle.

### Claim 34 (depends on 33)

The composition of claim 33, wherein the therapeutic agent is CT20p or a mutant CT20 peptide.

### Claim 35 (depends on 33)

The composition of claim 33, wherein the therapeutic agent is a mitotoxic peptide.

### Claim 36 (depends on 33)

The composition of claim 33, wherein the therapeutic agent is an anti-metastatic agent.

### Claim 37 (depends on 33)

The composition of claim 33, wherein the therapeutic agent is an antiandrogenic agent.

### Claim 38 (depends on 33)

The composition of claim 33, wherein the therapeutic agent is an anti-neoplastic agent.

### Claim 39 (depends on 33)

The composition of claim 33, wherein the solid tumor-specific cell protein is prostate specific membrane antigen (PSMA).

### Claim 40 (depends on 33)

The composition of claim 33, wherein the nanoparticles are polymeric nanoparticles.

### Claim 41 (depends on 33)

The composition of claim 33, wherein the nanoparticles are hyperbranched polyester nanoparticles (HBPE-NPs).

### Claim 42 (depends on 33)

The composition of claim 33, wherein the targeting ligand is a folate compound.

### Claim 43 (depends on 33)

The composition of claim 33 wherein the targeting ligand is a glutamate compound.

### Claim 44 (depends on 33)

The composition of claim 33, wherein the targeting ligand is a polyglutamated folate compound.

### Claim 45 (depends on 33)

The composition of claim 33, wherein the targeting ligand is glutamate azido urea.

### Claim 46 (depends on 33)

The composition of claim 33, wherein the targeting ligand is folate azido urea.

### Claim 47 (depends on 33)

The composition of claim 33, wherein the targeting ligand is glutamate azido urea

### Claim 48 (depends on 33)

The composition of claim 33, wherein the targeting ligand is a bifunctional glutamate-folate hybridized compound.

### Claim 49 (depends on 33)

The composition of claim 33, wherein the nanoparticle comprises a chelating ligand such as desferrioxamine (DFO).

### Claim 50 (depends on 33)

The composition of claim 33, wherein the imaging compound is a PET detectable compound.

### Claim 51 (depends on 33)

The composition of claim 33, wherein the PET detectable compound is 89Zr.

### Claim 52 (depends on 33)

The composition of claim 33, wherein the PET detectable compound is Cu or other PET detectable compounds.

### Claim 53 (depends on 33)

The composition of claim 33, wherein the composition comprises a polyglutamated folate-HBPE-DFO[CT20p]-nanoparticles.

### Claim 54 (depends on 33)

The composition of claim 33, wherein the nanoparticle further comprises PEG.

### Claim 55 (depends on 33)

The composition of claim 33, wherein the targeting ligand is at high density/valency.

### Claim 56 (depends on 33)

The composition of claim 33, wherein the targeting ligand is at low density/valency.

### Claim 57

A method for treating cancer, comprising:
a) administering to a subject diagnosed with prostate cancer an effective amount of a nanoparticle composition comprising, at least one nanoparticle conjugated with targeting ligand that is a substrate for a solid tumor-specific cell protein, wherein the nanoparticle further comprises an imaging compound and has a therapeutic agent encapsulated in the hydrophobic interior of the nanoparticle.

### Claim 58 (depends on 57)

The method of claim 57, wherein the cancer is prostate cancer.

### Claim 59 (depends on 58)

The method of claim 58, wherein the prostate cancer is castration resistant prostate cancer.

### Claim 60 (depends on 57)

The method of claim 57, wherein the cancer is breast cancer.

### Claim 61 (depends on 57)

The method of claim 57, wherein the cancer is colon cancer.

### Claim 62 (depends on 57)

The method of claim 57, wherein the cancer is pancreas cancer.

### Claim 63 (depends on 57)

The method of claim 57, wherein the cancer is lung cancer.

### Claim 64 (depends on 57)

The method of claim 57, wherein the therapeutic agent is CT20p or a mutant CT20 peptide.

### Claim 65 (depends on 57)

The method of claim 57, wherein the therapeutic agent is a mitotoxic peptide.

### Claim 66 (depends on 57)

The method of claim 57, wherein the therapeutic agent is an anti-metastatic agent.

### Claim 67 (depends on 57)

The method of claim 57, wherein the therapeutic agent is an antiandrogenic agent.

### Claim 68 (depends on 57)

The method of claim 57, wherein the therapeutic agent is an anti-neoplastic agent.

### Claim 69 (depends on 57)

The method of claim 57 wherein the solid tumor-specific cell protein is prostate specific membrane antigen (PSMA).

### Claim 70 (depends on 57)

The method of claim 57, wherein the nanoparticles are polymeric nanoparticles.

### Claim 71 (depends on 57)

The method of claim 57, wherein the nanoparticles are hyperbranched polyester nanoparticles (HBPE-NPs).

### Claim 72 (depends on 57)

The method of claim 57, wherein the targeting ligand is a folate compound.

### Claim 73 (depends on 57)

The method of claim 57, wherein the targeting ligand is a glutamate compound.

### Claim 74 (depends on 57)

The method of claim 57, wherein the targeting ligand is a polyglutamated folate compound.

### Claim 75 (depends on 57)

The method of claim 57, wherein the targeting ligand is glutamate azido urea.

### Claim 76 (depends on 57)

The method of claim 57, wherein the targeting ligand is folate azido urea.

### Claim 77 (depends on 57)

The method of claim 57, wherein the targeting ligand is glutamate azido urea

### Claim 78 (depends on 57)

The method of claim 57, wherein the targeting ligand is a bifunctional glutamate-folate hybridized compound.

### Claim 79 (depends on 57)

The method of claim 57, wherein the nanoparticle comprises a chelating ligand such as desferrioxamine (DFO).

### Claim 80 (depends on 57)

The method of claim 57, wherein the imaging compound is a PET detectable compound.

### Claim 81 (depends on 57)

The method of claim 57, wherein the PET detectable compound is 89Zr.

### Claim 82 (depends on 57)

The method of claim 57, wherein the PET detectable compound is CU or other PET detectable compounds.

### Claim 83 (depends on 57)

The method of claim 57, wherein the composition comprises a polyglutamated folate-HBPE-DFO[CT20p]-nanoparticles.

### Claim 84 (depends on 57)

The method of claim 57, wherein the nanoparticle further comprises PEG.

### Claim 85 (depends on 57)

The method of claim 57, wherein the targeting ligand is at high density/valency.

### Claim 86 (depends on 57)

The method of claim 57, wherein the targeting ligand is at low density/valency.

### Claim 87 (depends on 57)

The method of claim 57, further comprising administering another therapeutic or radiolabeled compound.

### Claim 88

A nanoparticle, comprising: a polymeric nanoparticle conjugated with targeting ligand that is a substrate for a solid tumor-specific cell protein, wherein the nanoparticle further comprises one or more imaging compounds and/or one or more therapeutic agents encapsulated in the hydrophobic interior of the nanoparticle.

### Claim 89 (depends on 88)

The nanoparticle of claim 88, wherein the therapeutic agent is CT20p or a mutant CT20 peptide.

### Claim 90 (depends on 88)

The nanoparticle of claim 88, wherein the therapeutic agent is a mitotoxic peptide.

### Claim 91 (depends on 88)

The nanoparticle of claim 88, wherein the therapeutic agent is an anti-metastatic agent.

### Claim 92 (depends on 88)

The nanoparticle of claim 88, wherein the therapeutic agent is an antiandrogenic agent.

### Claim 93 (depends on 88)

The nanoparticle of claim 88, wherein the therapeutic agent is an anti-neoplastic agent.

### Claim 94 (depends on 88)

The nanoparticle of claim 88, wherein the solid tumor-specific cell protein is prostate specific membrane antigen (PSMA).

### Claim 95 (depends on 88)

The nanoparticle of claim 88, wherein the nanoparticles are polymeric nanoparticles.

### Claim 96 (depends on 88)

The nanoparticle of claim 88, wherein the nanoparticles are hyperbranched polyester nanoparticles (HBPE-NPs).

### Claim 97 (depends on 88)

The nanoparticle of claim 88, wherein the targeting ligand is a folate compound.

### Claim 98 (depends on 88)

The nanoparticle of claim 88, wherein the targeting ligand is a glutamate compound.

### Claim 99 (depends on 88)

The nanoparticle of claim 88, wherein the targeting ligand is a polyglutamated folate compound.

### Claim 100 (depends on 88)

The nanoparticle of claim 88, wherein the targeting ligand is glutamate azido urea.

### Claim 101 (depends on 88)

The nanoparticle of claim 88, wherein the targeting ligand is folate azido urea.

### Claim 102 (depends on 88)

The nanoparticle of claim 88, wherein the targeting ligand is glutamate azido urea

### Claim 103 (depends on 88)

The nanoparticle of claim 88, wherein the targeting ligand is a bifunctional glutamate-folate hybridized compound.

### Claim 104 (depends on 88)

The nanoparticle of claim 88, wherein the nanoparticle comprises a chelating ligand such as desferrioxamine (DFO).

### Claim 105 (depends on 88)

The nanoparticle of claim 88, wherein the imaging compound is a PET detectable compound.

### Claim 106 (depends on 88)

The nanoparticle of claim 88, wherein the PET detectable compound is 89Zr.

### Claim 107 (depends on 88)

The nanoparticle of claim 88, wherein the PET detectable compound is CU or other PET detectable compounds.

### Claim 108 (depends on 88)

The nanoparticle of claim 88, wherein the nanoparticle comprises a polyglutamated folate-HBPE-DFO[CT20p]-nanoparticles.

### Claim 109 (depends on 88)

The nanoparticle of claim 88, wherein the nanoparticle further comprises PEG.

### Claim 110 (depends on 88)

The nanoparticle of claim 88, wherein the targeting ligand is at high density/valency.

### Claim 111 (depends on 88)

The nanoparticle of claim 88, wherein the targeting ligand is at low density/valency.

### Claim 112

A nanoparticle comprising a hyperbranched hyperbranched polyester functionalized with azide groups.

### Claim 113

A cancer therapeutic composition, comprising: at least one nanoparticle conjugated with a targeting ligand that is a substrate for a solid tumor-specific cell protein, wherein the nanoparticle further comprises one or more therapeutic agents encapsulated in the hydrophobic interior of the nanoparticle.

### Claim 114 (depends on 113)

The composition of claim 113, wherein the nanoparticle comprises more than one therapeutic agents.

### Claim 115 (depends on 113)

The composition of claim 113, wherein the therapeutic agent is CT20p or a mutant CT20 peptide

### Claim 116 (depends on 113)

The composition of claim 113, wherein the therapeutic agent is a mitotoxic peptide.

### Claim 117 (depends on 113)

The composition of claim 113, wherein the therapeutic agent is an anti-metastatic agent.

### Claim 118 (depends on 113)

The composition of claim 113, wherein the therapeutic agent is an antiandrogenic agent.

### Claim 119 (depends on 113)

The composition of claim 113, wherein the therapeutic agent is an anti-neoplastic agent.

### Claim 120 (depends on 113)

The composition of claim 113, wherein the solid tumor-specific cell protein is prostate specific membrane antigen (PSMA).

### Claim 121 (depends on 113)

The composition of claim 113, wherein the nanoparticles are polymeric nanoparticles.

### Claim 122 (depends on 113)

The composition of claim 113, wherein the nanoparticles are hyperbranched polyester nanoparticles (HBPE-NPs).

### Claim 123 (depends on 113)

The composition of claim 113, wherein the targeting ligand is a folate compound.

### Claim 124 (depends on 113)

The composition of claim 113 wherein the targeting ligand is a glutamate compound.

### Claim 125 (depends on 113)

The composition of claim 113, wherein the targeting ligand is a polyglutamated folate compound.

### Claim 126 (depends on 113)

The composition of claim 113, wherein the targeting ligand is glutamate azido urea.

### Claim 127 (depends on 113)

The composition of claim 113, wherein the targeting ligand is folate azido urea.

### Claim 128 (depends on 113)

The composition of claim 113, wherein the targeting ligand is glutamate azido urea

### Claim 129 (depends on 113)

The composition of claim 113, wherein the targeting ligand is a bifunctional glutamate-folate hybridized compound.

### Claim 130 (depends on 113)

The composition of claim 113, wherein the nanoparticle comprises a chelating ligand such as desferrioxamine (DFO).

### Claim 131 (depends on 113)

The composition of claim 113, wherein the nanoparticle further comprises PEG.

### Claim 132 (depends on 113)

The composition of claim 113, wherein the targeting ligand is at high density/valency.

### Claim 133 (depends on 113)

The composition of claim 113, wherein the targeting ligand is at low density/valency.

### Claim 134 (depends on 114)

The composition of claim 114, wherein the therapeutic agents are independently chosen from a DNA intercalator, topoisomerase inhibitor, microtubule stabilizer (taxol), receptor kinase inhibitor, kinase inhibitor, aromatase inhibitor, and anti-androgen.
